Roche stakes $700M on Nurix’s protein-degrading drug
Potentially worth up to $2.3 billion, the collaboration is a bet that drugs that can eliminate the “BTK” enzyme will prove superior to existing medi...
Potentially worth up to $2.3 billion, the collaboration is a bet that drugs that can eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.